Effect of Fluticasone in Severe Polyposis

Lund, Valerie J.; Flood, Joanne; Sykes, A. P.; Richards, D. H.

doi:10.1001/archotol.124.5.513

Cited by 150 publications

(114 citation statements)

References 14 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Nasal peak expiratory flow is a less useful measurement and therefore not recommended over inspiratory flow (60). Potential disadvantages such as that this method measures both sides together are mentioned (61,62). One could easily measure one side by occlusion of one nostril, yet such results have not been published, validated or correlated with perceived severity.…”

Section: Objective Methodsmentioning

confidence: 99%

“…Peak nasal inspiratory flow measurement has been used in several studies to determine nasal patency (64) with comparable sensitivity to acoustic rhinometry (65,66) and rhinomanometry (61,67,68). A strong positive correlation has been described between PNIF and the subjective sensation of nasal obstruction determined by means of questionnaires (44,69,70).…”

Section: Objective Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Evidence‐based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new GRADE system

Spronsen

Ingels

Jansen

et al. 2008

Allergy

View full text Add to dashboard Cite

Nasal congestion is an important symptom in nasal pathology and can be defined as an objective restriction of nasal cavity airflow because of mucosal pathology and/or increased mucus secretion (excluding anatomical variants). Using the new Grading Recommendations Assessment, Development and Evaluation system, evidence‐based recommendations are made that will encompass different clinical questions regarding diagnostic modalities of nasal congestion: (i) their usefulness in assessment of presence and severity of congestion; (ii) their usefulness in assessment of etiological pathology responsible for congestion; and (iii) their usefulness in follow up and treatment effectiveness evaluation of nasal congestion.

show abstract

Section: Objective Methodsmentioning

confidence: 99%

Section: Objective Methodsmentioning

confidence: 99%

Evidence‐based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new GRADE system

Spronsen

Ingels

Jansen

et al. 2008

Allergy

View full text Add to dashboard Cite

show abstract

“…The primary end point of this study was the reduction in NP score 19,20 at 8 weeks after the first dosing (1 month after the second dose). This total polyp score (TPS) is the sum of the right and left nostril scores, as evaluated by means of nasal endoscopy.…”

Section: Outcome Measuresmentioning

confidence: 99%

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Gevaert

Bruaene

Cattaert

et al. 2011

Journal of Allergy and Clinical Immunology

570

482

View full text Add to dashboard Cite

“…Other studies in patients with severe or bilateral polyposis found evidence of similar efficacy and tolerability of fluticasone propionate or beclomethasone dipropionate, with some evidence that fluticasone had a more rapid onset of action. [100][101][102] However, these reports lack the kinds of sizable effects that can be translated into practical application in a clinical setting. 103 The largest of these studies included fewer than 150 patients, with most enrolling fewer than 100 individuals, and the longest study was of only six months' duration.…”

Section: Acute Rhinosinusitis and Nasal Polyposis: Association With Amentioning

confidence: 99%

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Storms¹

2008

Primary Care Respiratory Journal

View full text Add to dashboard Cite

Allergic rhinitis (AR) is an extremely common health problem affecting 20 to 40 million Americans and between 10-25% of the world's population. Patients with AR suffer from both nasal symptoms (congestion, rhinorrhea, itching, and sneezing) and ocular symptoms (itching, redness, and tearing). The negative impact on sleep quality and quantity, and consequently on various aspects of the patient's life, is an under-recognised and under-treated component of AR morbidity. Nasal congestion, which is one of the most bothersome and prevalent symptoms of AR, is thought to be the leading symptom responsible for rhinitis-related sleep problems.In addition to reducing clinical symptoms, pharmacologic therapies for AR that specifically reduce inflammatory cells and mediators -and therefore nasal congestion and other symptoms -should also improve sleep quality and overall quality of life (QOL). Intranasal corticosteroids (INS) are the current mainstay of therapy for AR. Results of a number of clinical trials demonstrate that INS effectively reduce nasal congestion and ocular symptoms, improve sleep quality, and decrease daytime somnolence. Intranasal corticosteroids have also proved to be effective in reducing symptoms of acute rhinosinusitis and nasal polyposis, both of which also negatively impact on sleep quality. Intranasal corticosteroids are considered safe due to their low systemic bioavailability.

show abstract

Effect of Fluticasone in Severe Polyposis

Cited by 150 publications

References 14 publications

Evidence‐based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new GRADE system

Evidence‐based recommendations regarding the differential diagnosis and assessment of nasal congestion: using the new GRADE system

Mepolizumab, a humanized anti–IL-5 mAb, as a treatment option for severe nasal polyposis

Allergic rhinitis-induced nasal congestion: its impact on sleep quality

Contact Info

Product

Resources

About